Comparative Pharmacology
Head-to-head clinical analysis: QUALAQUIN versus QUINIDINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUALAQUIN versus QUINIDINE SULFATE.
QUALAQUIN vs QUINIDINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinine is a cinchona alkaloid that acts as a blood schizonticide against Plasmodium species. It inhibits heme polymerase in the parasite, leading to accumulation of toxic heme and parasite death. It also has weak gametocytocidal activity against P. vivax and P. malariae.
Quinidine is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction. It also inhibits potassium channels, prolonging repolarization, and has vagolytic and negative inotropic effects.
325-650 mg orally every 6 hours as needed for pain; maximum 2.6 g/day.
300-600 mg orally every 6-8 hours; maximum 2-4 g/day. Extended-release: 300-600 mg every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life approximately 8 hours in healthy adults; prolonged in hepatic impairment (up to 12-18 hours) and severe malaria (up to 14-20 hours).
Terminal elimination half-life is 6-8 hours in healthy adults; prolonged to 12-18 hours in heart failure, hepatic cirrhosis, or severe renal impairment (CrCl < 10 mL/min).
Renal (approximately 20% unchanged; remainder as metabolites); biliary/fecal (minor).
Renal excretion of unchanged drug accounts for 10-20% of elimination; hepatic metabolism (hydroxylation and N-oxidation) accounts for 70-80%; about 5% excreted in feces via biliary elimination.
Category C
Category A/B
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)